Zepbound and Wegovy go head-to-head in weight loss trial [93kUf783-R5]

Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head trial of the two blockbusters. In the study sponsored by Lilly, those on Zepbound lost an average of about 50 pounds over 72 weeks. Dr. Daniel Skovronsky, Eli Lilly chief scientific officer, spoke about the results on "Bloomberg Open Interest." -------- More on Bloomberg Television and Markets Like this video? Subscribe and turn on notifications so you don't miss any videos from Bloomberg Markets & Finance: Visit for business news & analysis, up-to-the-minute market data, features, profiles and more. Connect with Bloomberg Television on: X: Facebook: Instagram: Connect with Bloomberg Business on: X: Facebook: Instagram: TikTok: Reddit: LinkedIn: More from Bloomberg: Bloomberg Radio: Bloomberg Surveillance: Bloomberg Politics: Bloomberg Originals: Watch more on YouTube: Bloomberg Technology: Bloomberg Originals: Bloomberg Quicktake: Bloomberg Espanol: Bloomberg Podcasts: #grapefruit pill diet #dangers of taking diet pills #keto diet pills for men #acv keto for health scam